Last reviewed · How we verify
NCT06023160: NEOSII
Predicting Functional Outcome and Response to Therapy of Anti-NMDAR Encephalitis at Diagnosis
trial in Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis in 714 participants. Completed in 1 July 2024.
1 July 2023
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 714 |
| Start date | 1 December 2020 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across Netherlands |
Conditions studied
- Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis — all drugs for Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis →
Sponsor
Erasmus Medical Center
Who can join
Eligibility, any sex, with Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this international cohort study is to develop a prediction model for long-term outcome and response to first-line immunotherapy of anti-NMDAR Encephalitis, already at the moment of diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06023160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06023160 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06023160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing